MAIA Biotechnology, Inc. (MAIA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Chicago, IL, 美国. 现任CEO为 Vlad Vitoc.
MAIA 拥有 IPO日期为 2022-07-28, 13 名全职员工, 在 NYSE, 市值为 $54.9M.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
